Rekombinanter AXL (Tilvestamab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter AXL (Tilvestamab Biosimilar) Antikörper (ABIN7675645)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-AXL / UFO Reference Antibody (tilvestamab)
-
Sequenz
- EVQLVESGGG LVQPGGSLRL SCAASGYSFT DFYINWVRQA PGKGLEWVAR IFPGGDNTYY NEKFKGRFTL SADTSKSTAY LQMNSLRAED TAVYYCARRG LYYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK,DIQMTQSPSS LSASVGDRVT ITCRSSQSLV HSNGIPYLHW YQQKPGKAPK LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCSQGTHVP PTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
Produktmerkmale
- Anti-AXL / UFO Reference Antibody (tilvestamab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 146.16 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: AXL inhibitors
Conditions: Acute myeloid leukemia
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- AXL (Tilvestamab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- Synonyms: UFO, ARK, TYRO7, Anexelekto, AZF
-
Molekulargewicht
- 146.16 kDa
-
UniProt
- P30530
Target
-